AI
Sunday, May 02, 2021 8:29:22 AM
clear proof of my last point .. shift focus away from the facts which are not superbullish ..
but ok lets take it.
how do you deduce from my text that I am excited about crossover without addressing the things that my answer about comparing data which is the substance of my answer is incomprehensible unless one wants to remove focus from it.
with regard to ps progression ..
because the data is treated according to the original endpoints and the only ps progressions that are interesting are at patients who have received treatment as the argument is that it is DCVax it gives PS progression it makes no sense to take placebo in the "equation" plane and simple.
and to use that the company has not shared information about it as an argument amazes me a little. they are not exactly known for being the most open company
but my guess is that the reason is that throughout the period they have been in dialogue with the FDA and others about how to measure, characterize and not least categorize Ps progression .. and I also think it is one of the discussions that has delayed the process. just see that one has divided our original primary endpoint into 2 different secondary endpoints.
but ok lets take it.
how do you deduce from my text that I am excited about crossover without addressing the things that my answer about comparing data which is the substance of my answer is incomprehensible unless one wants to remove focus from it.
with regard to ps progression ..
because the data is treated according to the original endpoints and the only ps progressions that are interesting are at patients who have received treatment as the argument is that it is DCVax it gives PS progression it makes no sense to take placebo in the "equation" plane and simple.
and to use that the company has not shared information about it as an argument amazes me a little. they are not exactly known for being the most open company
but my guess is that the reason is that throughout the period they have been in dialogue with the FDA and others about how to measure, characterize and not least categorize Ps progression .. and I also think it is one of the discussions that has delayed the process. just see that one has divided our original primary endpoint into 2 different secondary endpoints.
